

Subject Index, 1989

Vol. 39, Nos. 1-6

A

Acquired immune deficiency syndrome (AIDS), 300

Adenomas, large bowel (See also, Colorectal cancer), 219-225

Adenomatous hyperplasia (See also, Atypical adenomatous hyperplasia)
Precursors of corpus carcinoma estrogens and, 179-192 (Classic)
Prostatic intraepithelial neoplasia, compared with, 366-367

Aflatoxin B₁, 207, 216

Alphafetoprotein, 208-209

American Cancer Society

Colorectal cancer detection guidelines of, 317

Great American Smokeout, 265 (announcement)

Guidelines

Breast cancer screening, 227-228

Detection of colorectal cancer (sigmoidoscopy), an update of, 317

A new era (Editorial), 1-2

Pesticide position statement of, 226

Publications, 60, 128

Quality assurance in the care of the cancer patient and, 197-200 (Editorial)

Report to the Nation: Cancer and the poor, 263-265

Socioeconomic status and, 261-262 (Editorial), 263-265, 284-285

Special report on cancer in the economically disadvantaged, 262, 270-278, 281-282, 284-285

Voluntarism and, 65-66 (Editorial)

Anemia (and cancer), 296-304

Announcements

Audrey Meyer Mars International

Fellowships in Clinical Oncology, 396

Great American Smokeout, 265

15th International Cancer Congress, 155

International Union Against Cancer (UICC)

International Cancer Research

Technology Transfer Project (ICRETT):

Personnel exchange in clinical

oncology, 156

Anorexia, 105-107, 300-301

Anticholinergics, 97

Antiemetic drugs, 96-100

Antihistamines, 97

Antineoplastic drugs, 301-302

Atypical adenomatous hyperplasia (AAH)

Fine needle aspiration biopsy and, 381-383

Prostate cancer and, 379-380

Transrectal ultrasound appearance of, 387

AZT (zidovudine), 300

B

Behavioral techniques, in management of anticipatory nausea and vomiting, 100-101

Benzamide, 97, 99

Benztropine, 97, 99

Biopsy

Bone marrow, 300

Cervix, 158-163

Liver, 209

Oral lesion, 79-80

Prostate, 326, 331-333, 380-386, 389

Bladder, prostate cancer and, 329-331

Bladder cancer

Incidence, 5, 12

Mortality, 7, 11, 13

Race and, 278-279

Survival rates, 4, 20, 23-25, 28, 30

Bleomycin, 301

Bone cancer

Incidence, 12

Liver metastases, 210

Mortality, 7, 13

Survival rates, 19, 23-26

Bone marrow

Anemia and, 300

Hypersplenism and, 303

Myelophthisic anemia and, 300

Brain and central nervous system cancer

Incidence, 12

Mortality, 7, 13

Survival rates, 19, 20, 23-26

Subject Index, 1989

Vol. 39, Nos. 1-6

A

Acquired immune deficiency syndrome (AIDS), 300

Adenomas, large bowel (See also, Colorectal cancer), 219-225

Adenomatous hyperplasia (See also, Atypical adenomatous hyperplasia)
Precursors of corpus carcinoma estrogens and, 179-192 (Classic)
Prostatic intraepithelial neoplasia, compared with, 366-367

Aflatoxin B₁, 207, 216

Alphafetoprotein, 208-209

American Cancer Society

Colorectal cancer detection guidelines of, 317

Great American Smokeout, 265 (announcement)

Guidelines

Breast cancer screening, 227-228

Detection of colorectal cancer (sigmoidoscopy), an update of, 317

A new era (Editorial), 1-2

Pesticide position statement of, 226

Publications, 60, 128

Quality assurance in the care of the cancer patient and, 197-200 (Editorial)

Report to the Nation: Cancer and the poor, 263-265

Socioeconomic status and, 261-262 (Editorial), 263-265, 284-285

Special report on cancer in the economically disadvantaged, 262, 270-278, 281-282, 284-285

Voluntarism and, 65-66 (Editorial)

Anemia (and cancer), 296-304

Announcements

Audrey Meyer Mars International

Fellowships in Clinical Oncology, 396

Great American Smokeout, 265

15th International Cancer Congress, 155

International Union Against Cancer (UICC)

International Cancer Research

Technology Transfer Project (ICRETT):

Personnel exchange in clinical

oncology, 156

Anorexia, 105-107, 300-301

Anticholinergics, 97

Antiemetic drugs, 96-100

Antihistamines, 97

Antineoplastic drugs, 301-302

Atypical adenomatous hyperplasia (AAH)

Fine needle aspiration biopsy and, 381-383

Prostate cancer and, 379-380

Transrectal ultrasound appearance of, 387

AZT (zidovudine), 300

B

Behavioral techniques, in management of anticipatory nausea and vomiting, 100-101

Benzamide, 97, 99

Benztropine, 97, 99

Biopsy

Bone marrow, 300

Cervix, 158-163

Liver, 209

Oral lesion, 79-80

Prostate, 326, 331-333, 380-386, 389

Bladder, prostate cancer and, 329-331

Bladder cancer

Incidence, 5, 12

Mortality, 7, 11, 13

Race and, 278-279

Survival rates, 4, 20, 23-25, 28, 30

Bleomycin, 301

Bone cancer

Incidence, 12

Liver metastases, 210

Mortality, 7, 13

Survival rates, 19, 23-26

Bone marrow

Anemia and, 300

Hypersplenism and, 303

Myelophthisic anemia and, 300

Brain and central nervous system cancer

Incidence, 12

Mortality, 7, 13

Survival rates, 19, 20, 23-26

Breast cancer

- Bone marrow involvement, 300
- Detection of, and community practice, 227-229
- Incidence, 3, 5, 12, 14, 40
- Irradiation and, 123-127 (letters)
- Liver metastases, 206
- Mammography screening pilot project, television-promoted, statistical evaluation, 252-254 (letter)
- Microangiopathic hemolytic anemia and, 301
- Mortality, 3, 7, 10, 13, 15, 17, 252 (letter)
- Reconstruction surgery, role of in, 40-49
- Survival rates, 4, 20, 23-30
- Years of life lost to, 37

Butyrophenones, 97-98

C

Cachexia, 105-107

Cannabinoids, 97, 99-100

Carcinoembryonic antigen (CEA)

- Colorectal cancer and, 50-57
- Liver cancer and, 209

Carmustine, 297

Central nervous system cancer (See, Brain and central nervous system cancer)

Cervical cancer, 157-178

Chemotherapy, 89-104, 110, 112, 211, 213-214, 297-302

Childhood cancers

- Hepatoblastoma, 208
- Liver cancer, 210
- Mortality rates, 7-8, 18
- Nausea and vomiting, 95-96, 100
- Survival rates among, 19, 26

Chlorpromazine, 96, 98

Cigarette smoking (See also, Smokeless Tobacco)

- Esophageal cancer, 270
- Lung cancer, 270
- Oral cancer, 68-71, 84
- Prevention, 293
- Socioeconomic status, 281

Cirrhosis of the liver, 207-208, 210

Cisplatin, 297, 301

Classics in Oncology

- Precursors of corpus carcinoma estrogens and adenomatous hyperplasia, 179-192
- Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas, 230-247

Colonoscopy, 221

Colorectal cancer

- American Cancer Society detection guidelines, 317
- Incidence, 3, 5, 12, 14
- Large bowel adenomas, 219-225
- Liver metastases, 206, 212
- Mortality, 3, 7, 10-11, 13, 15-16
- Recurrent cancer, 305-306
- Screening for, in community black churches, 115-118 (Opinion)
- Survival rates, 4, 20, 23-25, 27-28, 50-57

Colposcopy, 158-163

Computed tomography (See also, Radiology), 209, 212, 326

Corticosteroids, 97-98

D

Dentistry, 67-88

Dexamethasone, 98

Diagnosis-related groups (DRGs), 290

Diet

- Compliance to, and colorectal cancer screening, 115-118 (Opinion)
- Hyperalimentation, 105-114
- Macrobiotic diets, unproven method of cancer management, 248-251
- Megaloblastic anemia, 300-301
- Nausea and vomiting, 101
- Oral cancer, 69
- Prevention of cancer, 293
- Socioeconomic status, 281

Digital rectal examination

- Prostate cancer detection, 326, 329-334
- Transrectal ultrasound compared with, 331-332, 340-347, 352, 358

Diphenhydramine, 97, 99

DNA ploidy, 326, 333-334

Doxorubicin, 211, 297

Droperidol, 97-98

Duct-acinar dysplasia, 328-329, 377-379

E

Editorials

- Cancer and poverty: A double tragedy, 261-262
- Medical ethics, altruism, and the cancer patient, 133-134
- A new era, 1-2
- Progress against prostatic cancer, 325 (Guest Editorial)
- Quality assurance in the care of the cancer patient, 197-200
- Voluntarism and the American Cancer Society, 65-66

Erythroplasia, 72-76, 79

Erythropoiesis, 297

Esophageal cancer

- Incidence, 5, 12
- Liver metastases, 212
- Mortality, 11, 13
- Oral cancer associated with, 84-85
- Race and, 268, 270, 273, 283
- Survival rates, 4, 20, 23-25, 270

Estrogens

- Carcinogenic activity, 179-192 (Classic)
- Liver cancer and, 207
- Prostate cancer, role of, 327

Ethics, 133-134 (Editorial)

Ewing's sarcoma

- Survival rates, 19

F

FIGO nomenclature, 138-139, 143-144

5-Fluorouracil (5-FU), 211, 213-215

Flow cytometry, 333

FUDR, 211, 213-215

G

Genetics

- Prostate cancer, 327
- Race and, 278-279

Great American Smokeout, 265

Gynecologic cancer, 135-154, 157-178, 179-192, 320 (letter) (See also, specific genital sites)

H

Haloperidol, 97-98

Head and neck cancer, 83-84

Health care delivery system, 289-295

Health Insurance

- Access to health care, 290
- Inadequacy of, 291-293
- Socioeconomic status and, 272

Hepatitis B infection, 206-207

Hepatoblastoma, 208

Hodgkin's disease (See also, Lymphomas—non-Hodgkin's)

- Anemia, 297
- Autoimmune hemolytic anemia and, 302
- Incidence, 12
- Mortality, 7, 13, 38
- Recurrent cancer, 305
- Survival rates, 19, 20, 23-26, 30

Human papillomavirus (HPV), 164-168, 320 (letter)

Hyperalimentation, 105-114, 318-320 (letter) (See also, Total parenteral nutrition, TPN)

Hyperplasia

- Estrogen carcinogenic activity, 179-192 (Classic)
- Focal modular (liver), 207

Hypersplenism, 303

Hypnosis, 100

I

Immunoglobulin G (IgG), 302-303

Immunology

- Autoimmune hemolytic anemia, 302-303
- Chronic lymphocytic leukemia and, 61 (letter)
- Oral cancer and, 69, 84
- Prostate cancer detection, 329-330, 361-366
- Prostatic intraepithelial neoplasia and, 371-372, 378-379
- Red blood cell aplasia, 297

International Association of Cancer Victors and Friends (IACVF) (as recommender of unproven method of cancer management), 58-59

L

Laryngeal cancer

- Incidence, 12
- Mortality, 13
- Oral cancer associated with, 84-85
- Survival rates, 20, 23, 24, 25

Letters

- Ca, March/April cover, 256
- Cancer in the socioeconomically disadvantaged, 398
- Cancer statistics, 254-255, 399
- Chronic lymphocytic leukemia, 61
- Gynecologic cancers, early, 320
- Hyperalimentionation, 318-320
- Irradiation and breast cancer, 123-127
- Mammography, 252-254
- Medical ethics, 400
- Oral and oropharyngeal cancers, 397-398
- "The person with cancer," 398-399
- Skin cancer, nonmelanoma, 399-400
- Smokeless tobacco, 62
- Unorthodox cancer medicine, 62-64

Leukemias

- Autoimmune hemolytic anemia, 302
- Chronic lymphocytic, 61 (letter)
- Incidence, 3, 12, 14
- Megaloblastic anemia in, 301
- Mortality, 3, 7, 10-11, 13, 15, 17, 38
- Survival rates, 19, 20, 23-25, 30, 38
- Years of life lost to, 37

Leukoplakia, oral cancer and, 72-76, 80

Liver cancer, 206-218

Lorazepam, 99

"Lumpectomy," 123-124 (letter)

Lung cancer

- Alphafetoprotein and, 209
- Bone marrow involvement in, 300
- Incidence, 3, 5, 12, 14
- Liver metastases, 206, 210-212
- Microangiopathic hemolytic anemia and, 301
- Mortality, 3, 7, 10-11, 13, 15, 17
- Oral cancer associated with, 84-85
- Race and, 268-271, 282
- Recurrent cancer, 305
- Survival rates, 4, 20, 23-25, 27-28, 269-270
- Years of life lost to, 38

Lymphomas (non-Hodgkin's) (See also, Hodgkin's disease)

- Anemia and, 297
- Autoimmune hemolytic anemia and, 302-303
- Bone marrow involvement, 300
- Incidence, 3, 12
- Megaloblastic anemia, 301
- Mortality, 3, 7, 13, 38
- Survival rates, 19, 20, 23-26

M

Macrobiotic diets, unproven methods of cancer management, 248-251

Magnetic resonance imaging

- Liver cancer, 209, 212
- Prostate cancer, 326

Malnutrition, 105-114 (See also, Diet, Hyperalimentionation)

Mammography (See also, Breast cancer)

- Recommendations for, 40
- Screening pilot project, television-promoted, statistical evaluation, 252-254 (letter)

Mastectomy

- Breast reconstruction surgery following, 40-49
- Radiation therapy and, 123-124 (letter)

Medicare/Medicaid, 289-291, 293

Megaloblastic anemia, 300-301

Melanoma, malignant

- Bone marrow involvement, 300
- Incidence, 5, 12, 14
- Liver metastases, 212
- Mortality, 13, 15
- Recurrent cancer, 305
- Survival rates, 4, 20, 23-27, 30

Metastatic disease

- Cervical cancer, 147
- Iron deficiency, 300
- Liver, and, 206, 208, 210, 212-216
- Microangiopathic hemolytic anemia, 301
- Oral cancer, 83-86
- Prostate cancer, 326, 361, 376, 389
- Recurrent cancer psychological impact, 305-310
- Vulvar cancer, 149

Methotrexate, 211

Methylprednisolone, 97-98

Metoclopramide, 97, 99

Mitomycin C, 301

Modified radical mastectomy, 40 (See also, Mastectomy)

Multiple myeloma

- Anemia and, 297
- Incidence, 12
- Megaloblastic anemia, 301
- Mortality, 13
- Survival rates, 20, 23-25

Myelophthitic anemia, 300

Myeloproliferative disorders, 301

N

Nausea and vomiting (chemotherapy-related), 89-104

Needle core biopsy

- Fine needle aspiration biopsy compared with, 381
- Prostate cancer and, 380-381
- Prostate-specific antigen (PSA) and, 364-365, 372
- Prostatic intraepithelial neoplasia (PIN) and, 364-365, 371
- Transrectal ultrasound and, 337, 340-347, 358

Neutropenia, 300, 303

Nicotine (See, Cigarette smoking, Smokeless tobacco)

Nipple-areola reconstruction, 44, 48

O

Occupational hazards, socioeconomic status and, 281

Opiates, 92

Oral cancer, 67-88

Oral contraceptives, liver cancer and, 207, 210

Osteosarcoma

- Survival rates, 19

Ovarian cancer, 135-141, 144

- Anemia, 297
- Borderline lesions, 141-142
- Incidence, 3, 5, 12
- Mortality, 3, 7, 10, 13

Response of the human endometrium to granulosa cell tumor of, 180-181 (Classic)

Staging classification using the FIGO nomenclature, 138-139

Survival rates, 4, 20, 24, 27

Tumor spill, 142, 144

P

Pancreatic cancer

- Alphafetoprotein, 209
- Histologic description of, 237, 242-246 (Classic)
- Incidence, 3, 12, 14
- Liver cancer metastases, 210, 212
- Mortality, 3, 7, 10, 11, 13, 15
- Peptic ulcer, primary, of the jejunum and, 230, 231-247 (Classic)
- Survival rates, 20, 23-25

Papillomavirus infection, 164-167, 320 (letter)

Pap smear (See, Cervical cancer)

Parenteral (total) nutrition (See, Hyperalimentation)

Penile cancer, 148

Pentostatin, 297

Peptic ulcer, primary, of the jejunum, 230-247 (Classic)

Perphenazine, 98

Pesticides, American Cancer Society position statement, 226

Phenothiazines, 96-98

Ploidy (See, DNA ploidy)

Poverty (See, Socioeconomically disadvantaged)

Primary peptic ulcer (See, Peptic ulcer, primary, of the jejunum)

Prochlorperazine, 97-98

Prostate cancer

- Anatomic considerations in, 327
- Atypical adenomatous hyperplasia, 379-380
- Autopsy prevalence, 389
- Biopsy detection of, 333, 380-386
- Bone marrow involvement, 300
- Demography and, 376

Diagnostic techniques for, 325-393
Digital rectal examination and, 330-331
Epidemiology of, 326-327, 339-340
Incidence, 3, 5, 12, 14, 326, 339-340, 361, 376
Investigation/reporting of suspicious lesions, 387
Metastatic disease, 326, 361, 376, 389
Mortality, 3, 7, 11, 13, 15, 17, 326, 361, 376
Pathologic considerations, 328-329, 376-393
Physical examination, 329
Premalignancy, 361-375
Prostatic intraepithelial neoplasia (PIN), 377-379
Prostate-specific antigen (PSA) detection, 329-330, 361-375
Screening for, 329-330, 340-347, 361-366
Staging, 332-333
Survival rates, 4, 20, 22-23, 27-29, 334
Transrectal ultrasound and, 330-331, 337-360
Understaging of, 389-391

Prostate-specific antigen (PSA), 361-366

Prostatic acid phosphatase, 326, 333-334, 361-362 (See also, Prostate-specific antigen)

Prostatic intraepithelial neoplasia (PIN)
Adenomatous hyperplasia compared with, 366-367
Carcinoma associated with, 378-379
Grading system for, 367-371
Histologic features of, 377-379
Invasive carcinoma and, 367-371
Needle biopsy and, 371, 379
Predictive value of, 379
Premalignancy criteria, 376-380
Prostate cancer detection, generally, 329-330
Prostate-specific antigen and, 333
Spread patterns of, 377-378
Transrectal ultrasound appearance of, 387

Q

Quality assurance in cancer care

American Cancer Society Report to the Nation: Cancer in the poor, 263-265
Cancer and poverty: A double tragedy, 261-262 (Editorial)
Health care delivery system and, 201-205
Quality assurance in the care of the cancer patient, 197-200 (Editorial)

Questionable cancer therapies (See, Unproven methods of cancer management)

R

Radiation therapy

Anemia and, 300
Arteriography, 212
Breast cancer and, 123-127 (letters)
Liver cancer and, 211
Liver cancer metastatic disease and, 214-216
Total parenteral nutrition and, 110-112

Radical prostatectomy

Nerve-sparing technique and, 332
Prostate biopsy, 386-387
Prostate-specific antigen and, 363-364

Radiology (See also, Transrectal ultrasound)

Large bowel adenomas, 221-222
Liver cancer, 209, 212
Magnetic resonance imaging
Liver cancer, 209, 212
Prostate cancer, 326
Mammography, 40, 252-254 (letter)
Prostate cancer, 326

Radionuclide liver scan, 209

Recurrent cancer, experience of, 305-310

Relaxation procedures in the management of nausea and vomiting, 100-101

Renal cancer

Incidence, 12
Liver cancer metastases, 210
Mortality, 13
Survival rates, 19, 20, 23-26

Revici Method, unproven method of cancer management, 119-122

S

Screening

Breast cancer, 227-229, 252-254 (letter)
Large bowel adenomas, 219
Liver cancer, 207-208
Prostate cancer, 329-330, 340-347, 361-366

Sigmoidoscopy

American Cancer Society guidelines, 317
Large bowel adenomas, 221

Skin cancer (See also, Melanoma, malignant)

Incidence, 3, 12, 14
Mortality, 3, 7, 13, 15

Smokeless tobacco (See also, Cigarette smoking)

- Education and, 62 (letters)
- Oral cancer and, 69

Socioeconomically disadvantaged, the
261-295

- American Cancer Society Report to the Nation: Cancer and the poor, 263-265
- Cancer and poverty: A double tragedy, 261-262 (Editorial)
- Cancer incidence and, 267, 270-273, 281-282
- Cancer prevention and control and, 264
- Health care delivery system and, 289-295
- Health insurance and, 272, 291
- Recommendations of the American Cancer Society Special Report, 284-285
- Recurrent cancer and, 306
- Survival rates, 263, 266-270, 274-277, 283, 286

Squamous cell carcinoma

- Dissemination of, 83
- Microangiopathic hemolytic anemia, 301
- Oral cancer, 67 (See also, Oral cancer)
- Staging of, 84

Statistics, 3-20

- Breast cancer, 252-254 (letter)
- Clarification of, 254-255 (letter)
- Survival rates, 4, 19-32
- Years of life lost to cancer, trends in, 33-39

Stomach cancer

- Alphafetoprotein, 209
- Bone marrow involvement, 300
- Incidence, 5, 12
- Liver cancer metastases, 210, 212
- Microangiopathic hemolytic anemia, 301
- Mortality, 7, 10-11, 13, 17
- Race and, 268, 272
- Survival rates, 4, 20, 23-25

Surgery

- Breast reconstruction surgery, 40-49
- Gynecologic cancer, 151-152
- Liver cancer, 210-211
- Liver cancer metastatic disease, 212-213
- Oral cancer, 84
- Ovarian cancer, 135
- Peptic ulceration, primary, of the jejunum, 231 (Classic)
- Prostate biopsy, 380-391
- Prostate cancer PSA levels, 329-330
- Total parenteral nutrition and, 112-113

Survival rates (See also, specific sites)

- Long-term, 21-32
- Race differences, 266-270, 274, 286

Site and race variables, 4

- Socioeconomic status and, 263, 266-270, 274-277, 283, 286

Systematic desensitization as a treatment for nausea and vomiting, 100-101

T

Testicular cancer

- Alphafetoprotein, 209
- Incidence, 5, 12
- Mortality, 13
- Survival rates, 4, 20, 23, 26, 29-30

Testosterone, 327

THC, 97, 99-100

Thiethylperazine, 98

Thorotrast, 207

Thrombocytopenia, 300, 301, 303

Thyroid cancer

- Incidence, 12
- Mortality, 13
- Survival rates, 20, 23-27, 30

Tongue cancer (See also, Oral cancer)

- Incidence, 12
- Mortality, 13

Total parenteral nutrition (TPN)

- Clinical efficacy of, 111-113
- Controversy over, 105
- Metabolic effects of, 109-111
- Tumor growth and, 318-320 (letter)

Toxins

- Hepatic angiosarcoma, 206-207
- Liver cancer, 207
- Pesticides, American Cancer Society position statement, 226
- Socioeconomic status and, 281

Transrectal ultrasound (See also, Radiology, Ultrasonography), 326, 330-333, 337-360, 364-365, 371, 380-381, 387

Transurethral resection

- Prostate cancer diagnosed by, 383-386
- Transrectal ultrasound and, 350-351

Treatment-related anemia, 297-300

Treatment-related nausea and vomiting
(See, Nausea and vomiting)

Tumor markers

Liver cancer, 208

Prostate-specific antigen, 329-330,
361-366

Tumor spill, gynecologic cancer, 142-144

Tyrosinemia, 207

U

Ultrasonography, liver cancer, 209-210,
212 (See also, Transrectal ultrasound)

**Unproven methods of cancer
management**, 62-64 (letters)

International Association of Cancer Victors
and Friends, Inc. (IACVF), 58-59

Macrobiotic diets, 248-251

Revici Method, 119-122

Social implications of, 311-316

V**Viruses**

Hepatitis B infection, liver cancer and, 207

Human papillomavirus (HPV), 164-167,
320 (letter)

Vitamin B₁₂, 300-301

W

Waldenström's macroglobulinemia, 303

Wilson's disease, 207

Y

Years of life lost to cancer, trends in, 33-39

Z

Zidovudine, 300

Author Index, 1989

Vol. 39, Nos. 1-6

Abendroth RE, 123-124 (letter)
 Ahmad A, 397 (letter)
 Averette HE, 157-178

Baines CJ, 252-253 (letter)
 Bostwick DG, 376-393
 Bostwick, J III, 40-49
 Branch B, 320 (letter)
 Brawer, MK, 361-375

Carey LC, 230 (Classic)
 Cassileth BR, 63-64 (letter), 311-316
 Chmiel J, 50-57
 Choi KL, 115-118
 Clark RM, 125-126 (letter)
 Copeland EM III, 105-114, 319-320 (letter)

DeCosse JJ, 219-225
 DiSaia PJ, 135-154
 Dodd GR, 227-229
 Dodds ME, 115-118
 Drago JR, 326-336
 Dubrawsky N, 399 (letter)

Ellison EH, 231-247 (Classic)

Fenoglio-Preiser CM, 219-225
 Fink DJ, 227-229
 Freeman HP, 266-288
 Fremgen A, 50-57
 Friedman NB, 127 (letter)

Garfinkel L, 255, 399-400 (letters)
 Goldberg AT, 398-399 (letter)
 Gollan JL, 206-218
 Gusberg SB, 179-192 (Classic)

Hawk JC, 400 (letter)
 Holleb AI, 1-2, 65-66, 133-134, 197-200,
 261-262 (Editorials)

Imperato JP, 50-57

Kagan AR, 126 (letter)
 Kerman HD, 400 (letter)

Labiner GW, 126 (letter)
 Lange PH, 361-375
 Lasky HJ, 253-254 (letter)
 Laura JE, 62 (letter)
 Lee F, 337-360
 Lerner M, 289-295
 Lubera JA, 3-20

Maier ML, 253-254 (letter)
 Manoharan A, 61 (letter)
 Mashberg A, 67-88, 398 (letter)
 Mettlin C, 33-39
 Michalak VR, 399 (letter)
 Mitchell-Beren ME, 115-118
 Morgenstern L, 126 (letter)
 Morrow GR, 89-104
 Moss WT, 125 (letter)
 Murphy GP, 227-229, 325 (Guest Editorial)
 Myers MH, 21-32

Nelson JH, Jr., 157-178
 Nossaman NJ, 62 (letter)

Oberfield RA, 206-218
 Oswalt EM, 62 (letter)

Poma PA, 398 (letter)

Richart RM, 157-178
 Ries LAG, 21-32
 Ringrose CAD, 62-63 (letter)
 Rodes ND, 254-255 (letter)

Samit AM, 67-88, 398 (letter)
 Schnier MS, 63 (letter)
 Sener SF, 50-57
 Shapiro SJ, 126-127 (letter)
 Sherman D, 206-218
 Siders DB, 337-360
 Silverberg E, 3-20
 Sivak MV, Jr., 219-225
 Slade J, 256 (letter)
 Souba WW, 105-114, 319-320 (letter)
 Steele G, Jr., 206-218
 Steinberg D, 296-304
 Storey P, 318-319 (letter)
 Sylvester J, 50-57, 253-254 (letter)

Tattan DC, 320 (letter)
 Tepperman BS, 125 (letter)
 Thompson IL, 125 (letter)
 Torp-Pedersen ST, 337-360

Waskerwitz TR, 115-118
 Winchester DP, 201-205, 253-254 (letter)
 Worden JW, 305-310

Zanner JP, 398 (letter)
 Zollinger RM, 231-247 (Classic)

